Vaso Corporation
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsVaso Corporation is a diversified healthcare technology company operating in IT managed network services, professional sales of GE HealthCare capital equipment, and proprietary medical devices.
What they do
Vaso operates through three segments: VasoTechnology (IT) provides managed network infrastructure, transport, and security services; VasoHealthcare (Professional sales service) acts as an exclusive sales representative for GE HealthCare diagnostic imaging products to the middle market; VasoMedical (Equipment) designs, manufactures, and sells proprietary medical devices and software, including EECP therapy systems. The company divested its healthcare IT reseller business in November 2025.
Revenue drivers
- Professional sales service (VasoHealthcare) — Generates approximately 50% of total revenue and all operating income from commissions on sales of GEHC diagnostic imaging equipment.
- IT managed network services (VasoTechnology) — Provides managed network infrastructure, transport (as an FCC licensed carrier reseller with 175+ facility partners), and security services; contributes recurring service revenue.
- Equipment segment (VasoMedical) — Designs, manufactures, and sells proprietary medical devices and software, including EECP systems; includes international sales via Vasomedical Global and a 49% interest in EECP Global.
Recent performance
Revenue for fiscal 2025 was $89.1M, up from $86.8M in 2024, while net income improved to $1.6M from $951,000. Operating cash flow rose to $9.3M in 2025 from $3.3M in 2024. Quarterly revenue was $19.4M in Q1 2026, down from $27.0M in Q4 2025 and $22.7M in Q3 2025. The company reported cash and equivalents of $22.0M and total assets of $83.0M as of March 31, 2026.
Strategy
Management emphasizes maintaining the GEHC agreement, which expires December 31, 2030 (subject to early termination), and expanding the professional sales service segment. The IT segment focuses on managed network and security services following the divestiture of the healthcare IT reseller business. The equipment segment continues to develop and market proprietary medical devices, including EECP products, domestically and internationally.
Risks
- Concentration on GEHC — Substantial reliance on the GEHC agreement—approximately 50% of revenue and all operating income—creates vulnerability to termination or renegotiation.
- Economic and tariff exposure — U.S. economic downturns and tariff policies could disrupt demand for capital equipment and affect margins.
- Regulatory and reimbursement changes — Medical insurance reimbursement policies and regulatory actions could impact sales of proprietary devices and services.
- Technology and competition — Rapid changes in IT and healthcare, including AI, and competitive pricing could reduce demand for the company's offerings.
Outlook
Management did not provide specific financial guidance in the excerpts. The company expects to continue benefiting from the GEHC agreement through its current term, but risks remain from potential early termination. The divestiture of VasoHealthcare IT is expected to refocus the IT segment on managed network services. Forward-looking statements cite variability in order timing and customer acceptance as key near-term factors.